// App-Quantinova.ai

: Benefit‐risk Assessment of 10mg Daily Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

Researchers

Presenter

  • G.E. Raskob

Principal Investigators

  • W. Ageno

  • G.W. Albers

  • C.G. Elliot

  • J.L. Halperin

  • W.R. Hiatt

  • G.A. Maynard

  • G. Steg

  • J.I. Weitz

  • J. Albanese

  • Z. Yuan

  • B. Levitan

  • W. Lu

  • E. Suh

  • T.E. Spiro

  • C. Lipardi

  • E.S. Barnathan

  • A.C. Spyropoulos

Medical Centers

  • College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, United States

  • University of Insubria, Department of Medicine and Surgery, Varese, Italy

  • Stanford Stroke Center, Stanford University Medical Center, Stanford, United States

  • Intermountain Medical Center and the University of Utah, Department of Medicine, Salt Lake City, United States

  • The Cardiovascular Institute, Mount Sinai Medical Center, New York, United States

  • CPC Clinical Research, Aurora, United States

  • University of Colorado School of Medicine, Division of Cardiology, Aurora, United States

  • University of California, Davis, Davis, California, United States

  • DHU FIRE, University Paris‐Diderot, Assistance Publique‐Hôpitaux de Paris, and INSERM U‐1148, Paris, France

  • Imperial College, Royal Brompton Hospital, London, United Kingdom

  • McMaster University, Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada

  • Janssen Research & Development, LLC, United States

  • Thrombosis and Hematology Therapeutic Area, Clinical Development, Pharmaceuticals, Bayer U.S. LLC, Whippany, United States

  • The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institute for Medical Research, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services Northwell Health at Lenox Hill Hospital, New York, United States

Locations

  • United States

  • Italy

  • France

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Pulmonary/Respiratory Diseases

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Myocardial infarction

  • Deep vein thrombosis

  • Intracerebral hemorrhage

  • Pulmonary embolism

  • Stroke

Biomarkers

  • Creatinine

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved